title: Considering competing risks . . . Not all black and white.
authors.forename: Jane A
authors.initials: JA
authors.lastname: Cauley
authors.forename: Kristine E
authors.initials: KE
authors.lastname: Ensrud
mesh_terms: D019386:Alendronate / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000139:chemically induced*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D003657:Decision Making; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005260:Female; D050723:Fractures, Bone / Q000139:chemically induced*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D045162:Thiazolidinediones / Q000009:adverse effects*
chemical_list: D050071:Bone Density Conservation Agents; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D019386:Alendronate